I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Palents and Tredemarks. Washington. D C 20231 on 10/7/205

Arry Yost
Dale of Signature 10/7/2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dace et al.

Group Art Unit: 1639

Serial No.: 09/879,279

Examiner: Epperson, Jon D.

Filed: June 12, 2001

Docket No.: 1392/18/2

Confirmation No.: 3524

For:

IN VITRO CAPTURE OF NUCLEIC ACIDS VIA MODIFIED

OLIGONUCLEOTIDES AND MAGNETIC BEADS

DECLARATION PURSUANT TO 37 C.F.R. § 1.131

Commissioner for Patents Washington, D.C. 20231

Sir:

- We, Gayle Dace and William Kimmerly, are the co-inventors of the invention disclosed and claimed in the subject above-captioned U.S. Patent Application Serial No. 09/879,279.
- 2. We have had the opportunity to review the Official Action malled April 7, 2005 from the U.S. Patent and Trademark Office for the above-referenced U.S. patent application.
- We have also reviewed the following document cited by the United States
 Patent and Trademark Office in the Official Action mailed on July 13, 2004:

Serial No.: 09/879,279

- (a) U.S. Published Patent Application No. 2003/0077609 A1 (the '609 application).
- 4. The subject matter embodied in claims 1-8, 11-15, 18-24 and 31 of the subject U.S. Patent Application Serial No. 09/879,279 was invented prior to the earliest claimed priority date of March 25, 2001 of the '609 and '598 applications. The inventive activity occurred in the United States.
- 5. Attached hereto as **Exhibit A** is a true and accurate copy of consecutively numbered laboratory notebook pages documenting experiments performed involving the subject matter embodied in the pending claims. Exhibit A provides evidence of the subject matter recited in the pending claims and predates the earliest claimed priority date of March 25, 2001 of the '609 and '598 applications.
- 6. The first page of Exhibit A is a reproduction of p. 146 of a notebook entry entitled "New LNA Oligos" and records experimental conditions related to capturing specific target nucleotide sequences utilizing locked nucleic acids (LNAs), including providing nucleotide sequences of exemplary LNAs and characterizations of the LNAs and reagent quantities and conditions used in the experiments.
- 7. Specifically, p. 146 describes one or more modified oligonucleotide conjugates comprising at least one LNA and a linking molecule. The modified oligonucleotide referred to as "Torrey-2" comprises the listed sequence of (GC)₆, with the LNA residues in bold. The linking molecule used for "Torrey-2" was biotin.
- 8. The second page of Exhibit A is a reproduction of p. 147 of a notebook entry entitled "LNA Capture That Worked" and records further experimental conditions and reagents related to capturing specific target nucleotide sequences utilizing LNAs and experimental results.
- 9. The specific experimental conditions labeled "CN" and notated with a box pointing to plate T2NC01 are labeled as "WORKED" on the notebook entry of

Serial No.: 09/879,279


- p. 147. This comment is indicative of the successful capture of specific target nucleotide sequences utilizing an LNA.
- 10. Page 147 of the notebook describes incubating a sample of nucleic acids with the LNA conjugate to thereby form one or more hybridized duplexes, wherein each duplex comprises a target simple sequence repeat ("SSR") portion and an LNA conjugate. The boxed data indicates that 2.5µl of tomato library DNA was incubated with Torrey-2 LNA conjugate and Buffer C to form a hybridized duplex.
- 11. The third page of Exhlbit A is a reproduction of p. 150 of a notebook entry entitled "LNA Capture Protocol" and describes the protocol used to acquire the data set forth on pages 146 and 147, wherein the hybridized duplexes were contacted with a linking source so that the linking molecule formed a bond with the linking source to capture the LNAs. Specifically, the protocol recites that the biotinylated LNAs were contacted with streptavidin-coated magnetic beads and incubated to allow the biotin to form a bond with the streptavidin-coated beads.
- 12. The protocol on p. 150 recites that the hybridized duplexes were then separated from the sample of nucleic acids by extracting the linking source from the sample, followed by a washing step and an incubation step so that the target SSRs dissociate from the LNA conjugates and the magnetic beads. Specifically, the magnetic beads were separated from the sample of nucleic acids by use of a magnet, the beads washed eight times in Buffer C, and incubated in Buffer E in order to separate the SSRs from the beads. This step is also recited on the notebook entry of p. 147: "90°C in 150μl Buffer E 20 min."
- 13. The protocol on p.150 recites that the SSRs are ethanol precipitated overnight, and purified using a PCR purification kit.
- 14. The protocol on p.150 recites that DH12S cells were transformed with the SSR DNA, grown overnight, the colonies picked, and stored at a temperature of -80°C for sequencing.


Serial No.: 09/879,279

15. **Exhibit B** presents the results of sequence data chromatographs establishing that the SSRs were recovered and that the experiment was successful. Specifically, well E04 of plate T2NC01 was sequenced and an SSR (CA)₆ was discovered at bases 221-232 which is shown underlined. Further, well F09 of plate T2NC01 was sequenced and an SSR (CA)₆ was discovered at bases 131-142 which is shown underlined.

I hereby declare that all statements herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: <u>9-28-05</u>	Ву:	Sayle Dace, M.S. Gayle Dace, M.S.
Date:	Ву:	William Kimmerly





150	Project No Book No	TITLE	LNA	Capture	Protoce	losed on,	<u>۱۲ م</u>
From Page No.147					· · · · · · · · · · · · · · · · · · ·	·	200
		 <u>I</u>	NA Capture Pro	otocol	! .		
	Hybridization Buffer C:	100mM NaCl 10 mM Na ₂ PO ₄ (pH 7.0)			•	
	Dissociation Buffer E.	1.0 M Tris-Cl (µ 0.5 mM EDTA	Н 9.0)				
go i Acuto i roman	Genomic library in pBlu	escript KS-/sacB c	onstruct.				
A THE THE PARTY OF	Hybridization reaction: 1 ug library 75 ng 5'-biotinylated L.\(\) Buffer C to 60 ul	NA oligo (GT) ₆ (Pi	oligo LLC; Bou	lder, CO)			
THE PROPERTY OF THE PROPERTY O	Incubate at 80°C for 50 Add 60 ul of washed Dy for 80 min, shaking eve	vnal M-280 strepta	vidin-coated ma	gnetic beads and	I incubate in wa r in a 50°C incul	ter bath at 50°C bator).	
estatuta, viri	Very briefly spin to move all liquid to bottom of tube. Separate beads by use of Dynal magnet. Remove liquid and wash beads 8 times with 500 ul of Buffer C. After final wash, add 150 ul Buffer E and mix. Incubate at 90°C for 20 min (temperature specific to oligo						
	sequence). Remove and save liquions 875 ul of 100% EtOH. 500 ul ice cold 70% Et	d; discard beads.	Add 200 ul of dd	.H ₂ O (pH 5.0), 3 sin in cold at 14.	5 ul of 3 M NaC	OAc (pH 5.2), and in	
	PCR purification kit. Transform Life Technology BioRad Gene Pulser II Add 960 ul of SOC broplates containing 5% s place in -80°C for sequence.	, the settings are 2 oth, and gently shaucrose. Grow ove	5 uF, 200 Ω , and	l 1.8 kV 37°C. Plate 75 i	ıl of transformal	ion on LB amp	
THE STANFORM OF STANFORM STANF				;			
Witnessed & Und	erslood by me.	Date 12-19-01	Invented by	Layle D	Jaca	To P Date 3-/5-0/	age N

